Related Experiment Video
Updated: Jun 24, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Gemcitabine and carboplatin treatment in advanced NSCLC: a retrospective evaluation including elderly patients
Roberto Murialdo1, Davide Boy, Francesca Bertolotti
1Department of Internal Medicine, "S. Martino" Hospital, Genoa, Italy. rozzis752000@yahoo.it
Background:
Carboplatin-containing regimens are sometimes preferred for patients with advanced non-small cell lung cancer.
Methods:
Eighty-three patients with stage III-IV non-small cell lung cancer received 3 to 4 cycles of carboplatin AUC 5 on day 2 and gemcitabine 1250 mg/m2 on days 1 and 8 every 21 days.
Results:
The overall response rate was 43.4%. Results obtained from elderly and non-elderly groups were compared using the logrank method. Median overall survival and progression-free survival were 11 and 7 months, respectively (12 and 7 months, non-elderly group; 6.5 and 5 months, elderly group, P = 0.28 and 0.25 respectively). Grade 3-4 toxicity included neutropenia, thrombocytopenia, anemia, nausea/vomiting, and diarrhea. Incidences of grade 3-4 toxicity were similar for elderly and non-elderly patients.
Conclusions:
Data confirm that carboplatin-gemcitabine is an active and well-tolerated regimen in advanced non-small cell lung cancer and could be investigated in elderly patients.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Drug Dosing: Geriatric Patients
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism